CAS: 52549-17-4; 2-(5H-Chromeno[2,3-B]Pyridin-7-yl)Propanoic Acid

该化合物是一种主要用于其止痛和抗炎特性的非类固醇抗炎药物,主要用于止痛和抗炎特性,通过抑制环氧酶(COX)发挥作用,从而减少 plastlandin合成并减轻疼痛和炎症. Pranoprofen 特别有效地治疗眼炎,如后性能条件和结节炎,因为它有利于渗透到眼部组织中.其低系统吸收能最大限度地减少不利影响,使之适合局部应用.化合物展示了快速的行动和持续效果,确保了可靠的治疗结果.Pranoprofen 的稳定性和与各种配方的兼容性进一步增强了其在药物制剂中的效用.

结构式图片

相似化合物

146330-68-9 52549-17-4 86618-09-9

欧盟法规

ECHA物质C&L通报

上下游产品

CAS号52549-19-6 α-甲基-5-氧代-5H-[1...

合成工艺路线路线简述

    7-(1,1-Dimethoxy-2-Hydroxypropyl)-5H-[1]-Chromeno[2,3-B]Pyridine置于氯化亚砜,三乙胺,盐酸体系中,用 二氯甲烷,水 作为反应溶剂,化学反应 6.0H,以61%的收率获得产物泊米布洛芬
    参考文献:一种新的普拉洛芬的制备方法
    标题:一种新的普拉洛芬的制备方法
    摘要:本发明公开了一种新的普拉洛芬的制备方法,具有收率高,杂质少,安全,环保的优点,包括以下步骤:通过使用5H‑[1]‑苯并吡喃[2,3‑b]吡啶和丙酰氯直接酰基化,然后进行溴代,第三步使用叔丁醇钾或叔丁醇钠水解,最后重排得到普拉洛芬:

    海关参考信息

    专利信息


    专利号:US-2024287520-A1
    优先权日:2021-06-30
    标题:Method for synthesis of linkage modified oligomeric compounds
    发明人:RODRIGUEZ ANDREW A
    权利人:IONIS PHARMACEUTICALS INC
    摘要:The present disclosure provides methods of synthesizing modified oligonucletodies and oligomeric compounds (including oligomeric compounds that are antisense agents or portions thereof) comprising a modified oligonucleotide having at least one modified internucleoside linking group. In certain embodiments, the present disclosure provides stabilized formulations of certain sulfonyl azides for use in the synthesis of olignonucleotides comprising one or more sulfonyl phosphoramidate linkages. Some embodiments provide stabilized compositions of high energy reagents that may be used in the synthesis of modified oligonucleotides, allowing for safe process scale preparation thereof.

    专利号:US-8546532-B2
    优先权日:2008-04-17
    标题:Synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
    发明人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS
    权利人:BONNIN DUSTAN; ZANELLI ERIC; MATHERS THOMAS; DECLION PHARMACEUTICALS INC
    摘要:The instant invention comprises a process for the solid phase synthesis of directed epitope peptide mixtures useful in the treatment and diagnosis of protein conformational disorders, such process defined by a set of rules regarding the identity and the frequency of occurrence of amino acids that substitute a base or native amino acid of a known epitope. The resulting composition is a mixture of related peptides for therapeutic use. The invention also pertains to the process of generating antibodies using the directed epitope peptide mixtures as the antigens, and antibodies generated by such process, useful in the treatment and diagnostics of the said protein conformational disorder.

    专利号:US-2012029226-A1
    优先权日:2009-02-06
    标题:Method for the synthesis of chiral alpha-aryl propionic acid derivatives
    发明人:KAPTEIN BERNARDUS; VLIEG ELIAS; NOORDUIN WILLEM LIEUWE
    权利人:KAPTEIN BERNARDUS; VLIEG ELIAS; NOORDUIN WILLEM LIEUWE
    摘要:The present invention provides a method for the synthesis of optically pure α-aryl propionic acid derivatives comprising subjecting the corresponding racemic α-aryl propionic acid derivatives to high sheer or impact forces, such as grinding.

    专利号:US-12264143-B2
    优先权日:2020-12-17
    标 题:Synthesis of cannabinoids and cannabinoid precursors, and related compounds, formulations, and methods of use
    发明人:SAMMIS GLENN M; ROGGEN MARKUS
    权利人:NALU BIO INC
    摘要:Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-8304409-B2
    优先权日:2002-07-03
    标 题:Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
    发明人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI
    权利人:EARL RICHARD A; EZAWA MAIKO; FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; KHANAPURE SUBHASH P; LETTS L GORDON; LIN CHIA-EN; RANATUNGE RAMANI R; RICHARDSON STEWART K; SCHROEDER JOSEPH D; STEVENSON CHERI A; WEY SHIOW-JYI; NICOX SA
    摘要:The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.
    辽宁博美医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.biosunpharm.com
    企业联系电话:024-24524889,18640309171👤
    📞辽宁博美医药科技有限公司 ⚠️参考联系方式
    联系人:李伟
    电话:024-24524889,18640309171
    手机:18640309171
    传真:024-24524889
    邮箱:sales@biosunpharm.com
    通信地址: 本溪经济开发区药都研发中心
    邮编: 110015
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:本溪经济开发区药都研发中心
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    杭州众昌科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.chemlands.com
    企业联系电话:+86-571-88932183👤
    📞杭州众昌科技有限公司 ⚠️参考联系方式
    联系人:俞洪正
    电话:+86-571-88932183
    手机:13858087099
    传真:+86-571-85120438
    邮箱:sales@chemlands.com
    通信地址: 浙江杭州市文三路508号天苑大厦19楼E座 /浙江省杭州湾上虞工业园区经一路2#
    邮编: 310013
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:浙江杭州市文三路508号天苑大厦19楼E座 /浙江省杭州湾上虞工业园区经一路2#
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    沈阳海诺威医药科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.hinewy.com
    企业联系电话:13709882332,13358863169;024-31682991👤
    📞沈阳海诺威医药科技有限公司 ⚠️参考联系方式
    联系人:董女士;董经理
    电话:13709882332,13358863169;024-31682991
    手机:13709882332;13358863169
    传真:QQ:65860507
    邮箱:Sales-hinewy@hinewy.com
    通信地址: 沈阳市沈河区大南街勒石里11-1号 2-2-1
    邮编: 110000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:沈阳市沈河区大南街勒石里11-1号 2-2-1
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    北京世纪迈劲生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.mediking.cn
    企业联系电话:010-81769521👤
    📞北京世纪迈劲生物科技有限公司 ⚠️参考联系方式
    联系人:高经理
    电话:010-81769521
    手机:15901403431
    传真:010-81769652
    邮箱:sales@mediking.cn
    通信地址: 北京市亦庄经济技术开发区永昌中路甲6号院A座4层
    邮编: 100176
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:北京市亦庄经济技术开发区永昌中路甲6号院A座4层
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Shimada H, Kobayashi Y, Tanahashi S, Kawase A, Ogiso T, Iwaki M. Correlation between glucuronidation and covalent adducts formation with proteins of nonsteroidal anti-inflammatory drugs. Eur J Pharm Sci. 2018 Jan 15;112:132-138. doi: 10.1016/j.ejps.2017.11.018. Epub 2017 Nov 22. doi: 10.5414/CP203047. doi: 10.1080/15569527.2017.1303706. Epub 2017 Mar 27. doi: 10.1016/j.jconrel.2017.03.003. Epub 2017 Mar 6. doi: 10.1016/j.ijpharm.2016.07.055. Epub 2016 Jul 30. Epub 2016 Jul 16. doi: 10.1016/j.ijpharm.2016.01.071. Epub 2016 Feb 1. doi: 10.1007/s00417-016-3278-1. Epub 2016 Jan 21. doi: 10.1007/s00417-016-3277-2. Epub 2016 Jan 21. doi: 10.3109/08982104.2015.1120746. Epub 2016 Jan 19. doi: 10.3346/jkms.2015.30.12.1856. Epub 2015 Nov 30.
    12: An SH, Kwon YH. Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2016 Aug;254(8):1489-96. doi: 10.1007/s00417-015-3215-8. Epub 2015 Nov 9. doi: 10.1002/jps.24543. Epub 2015 Jun 17. doi: 10.1002/chir.22436. Epub 2015 Apr 22. Chinese. doi: 10.1016/j.ejpb.2015.01.026. Epub 2015 Feb 11. doi: 10.3109/03639045.2014.971028. Epub 2015 Jul 21. doi: 10.1089/jop.2013.0244. doi: 10.1002/jps.24101. Epub 2014 Aug 4.

    合成参考文献


    参考文献:10.1016/j.jchromb.2011.06.043
    摘要:Wang H, Ji J, Zeng S. Biosynthesis and stereoselective analysis of (-)- and (+)-zaltoprofen glucuronide in rat hepatic microsomes and its application to the kinetic analysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 15;879(24):2430–6. doi: 10.1016/j.jchromb.2011.06.043.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知